HDAC3 MEDIATES CARDIOPROTECTION OF REMIFENTANIL POSTCONDITIONING BY TARGETING GSK-3 beta IN H9c2 CARDIOMYOCYTES IN HYPOXIA/REOXYGENATION INJURY

摘要

Background: Remifentanil postconditioning (RPC) confers robust cardioprotection against ischemia/reperfusion (I/R) injury. We recently determined that HDAC3 was involved in RPC-induced cardioprotection. However, the role of HDAC3 and its possible mechanisms in RPC-induced cardioprotection are unknown, which we aimed to evaluate in an in vitro hypoxia/reoxygenation (HR) model. Methods: Myocardium I/R injury was established after HR with H9c2 cardiomyoblasts. Cell viability and apoptosis were evaluated usingCCK-8 and flow cytometry of HR-injured cardiomyoblasts treated with or without RPC. Furthermore, effects of RPC on HDAC3 protein and mRNA expression were evaluated with Western blot and quantitative real-time PCR analyses, whereas GSK-3 beta expression was measured with Western blot. Results: RPC increased cell viability and reduced cell apoptosis (P0.05) in H9c2 cardiomyoblasts subjected to HR injury. In addition, RPC promoted the phosphorylation of GSK-3 beta at Ser9 site (P0.05) and suppressed the protein and mRNA expression of HDAC3 (P0.05). Lentiviral-transduced overexpression of HDAC3 had no significant effects on HR injury while attenuating the cardioprotective effects of RPC on cell viability and apoptosis (P0.05), GSK-3 beta phosphorylation (P0.05) in H9c2 cardiomyoblasts. Conclusions: RPC attenuates apoptosis in H9c2 cardiomyoblasts after HR injury by downregulating HDAC3-mediated phosphorylation of GSK-3 beta. Our findings suggest that HDAC3, and its cross talk function with GSK-3 beta, may be a promising target for myocardium I/R injury.